Chemokine Mechanisms in Chronic Pelvic Pain
The purpose of this study is to identify biomarkers that can be utilized in the diagnosis of chronic pelvic pain syndrome in men.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Chemokine Mechanisms in Chronic Pelvic Pain|
- Correlation of cytokines/chemokines/proteins with CPPS symptoms [ Time Frame: Over the period of a year ] [ Designated as safety issue: No ]Cytokines/chemokines/proteins will be correlated with symptom scores from patients in a longitudinal fashion.
Biospecimen Retention: Samples With DNA
Expressed prostatic secretions, urine with or without cells, blood for cells and plasma
|Study Start Date:||May 2010|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2017 (Final data collection date for primary outcome measure)|
The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
Chronic pelvic pain is the hallmark of patients with chronic pelvic pain syndrome (CPPS), a non-bacterial category of prostatitis that is a significant source of morbidity in American men. The cause of CPPS is unknown and there is a lack of convenient biomarkers for diagnosis of this syndrome. This project will examine the expression of biomarkers in expressed prostatic fluid from adult men with and without a diagnosis of CPPS. Thus our specific aim is to validate the use of the chemokines MCP-1 and MIP-1alpha and mast cell tryptase as biomarkers for CPPS in humans and correlate their levels with CPPS symptoms.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01676857
|Contact: Darlene Marko, RNemail@example.com|
|Contact: Praveen Thumbikat, PhDfirstname.lastname@example.org|
|United States, Illinois|
|Northwestern Medical Faculty Foundation||Recruiting|
|Chicago, Illinois, United States, 60611|
|Principal Investigator: Praveen Thumbikat, PhD|
|Principal Investigator:||Praveen Thumbikat, PhD||Northwestern University|